Eisai licenses Zebinix from Bial-Portela

Bial-Portela (S. Mamede do Coronado, Portugal) granted Eisai (Tokyo:4523; Osaka:4523) exclusive rights to market Zebinix eslicarbazepine in Europe. On Thursday, the sodium channel antagonist received a positive opinion from EMEA's CHMP for adjunctive treatment of partial-onset seizures in adult epilepsy patients. A decision is expected next quarter. ...